In a filing, Adma Biologics Inc revealed its Director ELMS STEVE unloaded Company’s shares for reported $3.94 million on Jun 16 ’25. In the deal valued at $20.24 per share,194,749 shares were sold. As a result of this transaction, ELMS STEVE now holds 87,330 shares worth roughly $1.78 million.
Then, ELMS STEVE sold 137,931 shares, generating $2,871,723 in total proceeds. Upon selling the shares at $20.82, the Director now owns 282,079 shares.
Before that, ELMS STEVE sold 92,941 shares. Adma Biologics Inc shares valued at $2,015,890 were divested by the Director at a price of $21.69 per share. As a result of the transaction, ELMS STEVE now holds 2,031,730 shares, worth roughly $41.45 million.
A number of analysts have revised their coverage, including Mizuho’s analysts, who began to cover the stock in mid October with a ‘”a Buy”‘ rating. Raymond James also remained covering ADMA and has increased its forecast on November 11, 2021 with a “Strong buy” recommendation from previously “an Outperform” rating. Cantor Fitzgerald started covering the stock on November 09, 2021. It rated ADMA as “an Overweight”.
Price Performance Review of ADMA
On Monday, Adma Biologics Inc [NASDAQ:ADMA] saw its stock fall -1.97% to $20.40. Over the last five days, the stock has lost -2.25%. Adma Biologics Inc shares have risen nearly 18.95% since the year began. Nevertheless, the stocks have risen 89.24% over the past one year. While a 52-week high of $25.67 was reached on 04/28/25, a 52-week low of $10.21 was recorded on 03/04/25.
Levels Of Support And Resistance For ADMA Stock
The 24-hour chart illustrates a support level at 19.94, which if violated will result in even more drops to 19.49. On the upside, there is a resistance level at 20.91. A further resistance level may holdings at 21.43.
The most recent change occurred on June 04, 2019 when Jefferies began covering the stock and recommended ‘”a Buy”‘ rating along with a $8 price target.
